Piperaquine
与青蒿素联合用于抑制HIV-1复制
| 规格 | 价格 | 货期 | 数量 |
|---|---|---|---|
| 10mg | ¥2579.00 | 10-15工作日发货 | |
| 25mg | ¥4740.00 | 10-15工作日发货 | |
| 50mg | ¥8939.00 | 10-15工作日发货 | |
| 100mg | ¥16859.00 | 10-15工作日发货 |
特色产品
- 用于免疫印迹和质谱分析等后续操作
- 适用于30 KDa-130 KDa大小的蛋白
- 可将信号灵敏度提高100倍
- 同时保持稳定的特异性和分辨率
- 提供更高的转录效率并抑制免疫激活
- 使用5-moUTP和Cy5-utp修饰
产品描述
IC50: 9.8 to 217.3 nM for P. falciparum isolates
Piperaquine, an antimalarial drug, is first synthesised in the 1960s and extensively used as prophylaxis and treatment during the next 20 years.
In vitro: In 280 P. falciparum isolates, the IC50 for piperaquine ranged from 9.8 nM to 217.3 nM and a significant but low correlation was observed between the IC50 values for piperaquine and chloroquine. However, the coefficient of determination indicated that only 2.1% of the variation in the response to piperaquine was explained by the variation in the response to chloroquine. Moreover, the mean value for piperaquine was 74.0 nM in the Pfcrt K76 wild-type group and 87.7 nM in the 76T mutant group and such difference was not significant [1].
In vivo: Male SD rats were orally administered piperaquine or as a short-term i.v. infusion. Results showed that piperaquine disposition was best described by a 3-compartment model with a rapid initial distribution phase after i.v. administration. The PK of piperaquine was characterized by a low clearance, a large volume of distribution and a long terminal half-life [2].
Clinical trial: The safety and efficacy of a combination of dihydroartemisinin (DHA) and piperaquine was assessed in patients with uncomplicated falciparum malaria. Mean total DHA and piperaquine doses were 9.1 and 73.9 mg/kg, respectively, for children and 6.6 and 52.9 mg/kg for adults. Results showed that excluding the results for 1 child who died, there was a 96.9% 28-day cure rate. Side effects were reported by 22 patients but did not necessitate premature cessation of therapy [3].
References:
[1] Pascual A et al. In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene. Malar J. 2013 Nov 25;12:431.
[2] Tarning J, Lindegardh N, Sandberg S, Day NJ, White NJ, Ashton M. Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat. J Pharm Sci. 2008 Aug;97(8):3400-10.
[3] Denis MB, Davis TM, Hewitt S, Incardona S, Nimol K, Fandeur T, Poravuth Y, Lim C, Socheat D. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis. 2002 Dec 15;35(12):1469-76.
产品性质
| 物理外观 | A crystalline solid |
| CAS号 | 4085-31-8 |
| 分子式 | C29H32Cl2N6 |
| 分子量 | 535.5 |
| 化学名称 | 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis[7-chloro-quinoline |
| 溶解度 | ≤0.2mg/ml in DMSO |
| SMILES | ClC1=CC2=C(C=C1)C(N3CCN(CC3)CCCN4CCN(CC4)C5=C6C=CC(Cl)=CC6=NC=C5)=CC=N2 |
| 存储条件 | -20°C |
| 运输条件 | 蓝冰 |
产品应用 (实验数据来自文献,APExBIO并未验证,仅供参考)
IC50和靶点
| 生物活性描述 | 哌喹是一种双喹啉化合物;可抑制来自疟疾感染患者的恶性疟原虫分离株的体内外生长;IC50 值为 11.8-217.3 nM。 |



沪公网安备 31011002003500